BIRC5 and cancer: The lentiviral CRISPR/Cas9 nickase in these cancer cells led to BIRC5 gene editing, which resulted in the inhibition of EMT by upregulating epithelial cell markers and downregulating mesenchymal markers in both ovarian cancer cells [70].